Press Releases

To read the latest news about Aerovance, we invite you to click on the links below to view recent press releases.

06.07.2010 Phase 2b Clinical Trial Results Show Aerovance’s Aerovant™ is Effective in Patients with Eosinophilic Asthma

Phase 2b Clinical Trial Results Show Aerovance’s Aerovant™ is Effective in Patients with Eosinophilic Asthma Statistically Significant Results Support Novel Inhaled IL-4/IL-13 Inhibitor’s Continued ...

11.04.2009 Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant™ for Treatment of Uncontrolled Asthma

Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant™ for Treatment of Uncontrolled Asthma BERKELEY, Calif., Nov. 3, 2009 – Aerovance Inc. today ...

04.07.2009 Aerovance Secures $38 Million in Equity Financing

BERKELEY, Calif., April 7, 2009 – Aerovance Inc. today announced that it has secured $38 million in additional equity financing. In previous transactions since formation in 2004, the company has raised $92 million in ...

03.02.2009 Aerovance Initiates Phase IIb Clinical Trial with Aerovant™ for the Treatment of Uncontrolled Asthma

BERKELEY, Calif., March 2, 2009 – Aerovance Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) ...

02.09.2009 Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer

BERKELEY, Calif., Feb. 9, 2009 – Aerovance Inc. today announced the appointment of Babatunde A. Otulana, M.D., to the position of senior vice president and chief medical officer. Dr. Otulana, 52, will provide medical ...

10.07.2008 Data Show Aerovance’s Aerovant™ Inhalation Powder is Well Tolerated in Asthma Patients

BERKELEY, Calif., Oct. 7, 2008 – Aerovance Inc. today reported pharmacokinetic (PK) and safety data from a Phase I trial of its AEROVANT inhalation powder that demonstrate good tolerability with no evidence of local ...

03.28.2008 Aerovance Secures $20 Million in Debt Financing

BERKELEY, Calif., March 28, 2008 - Aerovance Inc. today announced it has secured $20 million in venture debt financing. Oxford Finance Corporation led the syndicate, which includes Silicon Valley Bank and Comerica Bank. ...

10.30.2007 Aerovance Promotes Anthony Rimac to Vice President, Chief Financial Officer

BERKELEY, Calif., Oct. 30, 2007 – Aerovance Inc. today announced the promotion of Anthony M. Rimac to vice president and chief financial officer. Rimac, 44, previously served as Aerovance’s vice president of ...

03.27.2007 Aerovance Closes Second Tranche of $60 Million Series C Financing

Company Prepared to Advance Novel Asthma Drug Into Phase IIb Trial BERKELEY , Calif. , March 27, 2007 – Aerovance, Inc. today announced it has closed the $32 million second tranche of its $60 million Series C ...

02.01.2007 Aerovance Names Mark L. Perry President and CEO

BERKELEY, Calif., Feb. 1st, 2007 – Aerovance, Inc. today announced the appointment of Mark L. Perry, currently the company’s executive chairman, as president and chief executive officer. Perry, 51, has been a ...

01.03.2007 Aerovance Announces Positive Top-Line Results from Phase 2a Trial of Inhaled AEROVANT™ in Asthma Patients

Drug Candidate Reduces Severity of Asthma Attacks by 72 Percent Compared to Baseline BERKELEY , Calif. , Jan. 3, 2007 – Aerovance, Inc. today announced positive top-line results from a Phase 2a trial of inhaled ...

12.18.2006 Aerovance Adds Accomplished Product Commercialization Executive to Leadership Team

David A. Happel Brings Respiratory Disease Product Management Expertise to Company BERKELEY , Calif. , Dec. 18, 2006 – Aerovance, Inc. today announced the addition of David A. Happel, an accomplished product ...

11.16.2006 Aerovance Announces Key Board Appointments Mark L. Perry Appointed Executive Chairman, Douglas E. Williams Ph.D. Joins as Director

BERKELEY , Calif. , Nov. 16, 2006 – Aerovance Inc., a biopharmaceutical company with a portfolio of clinical-stage drugs targeting severe respiratory and inflammatory diseases, today announced that Mark L. Perry, current ...